Italia markets open in 14 minutes

Global Blood Therapeutics, Inc. (0IVZ.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
67,86+0,03 (+0,05%)
Alla chiusura: 05:10PM BST
Schermo intero
Chiusura precedente67,83
Aperto67,88
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno67,88 - 67,88
Intervallo di 52 settimane67,88 - 67,88
Volume63
Media VolumeN/D
Capitalizzazione43,902M
Beta (5 anni mensile)0,46
Rapporto PE (ttm)N/D
EPS (ttm)-4,86
Prossima data utili02 nov 2022 - 07 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022

    Congress Moves to Expand Funding for National Network of Specialized Treatment Centers and Community Organizations for Sickle Cell Disease PatientsSOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced its support for the Sickle Cell Disease Treatment Centers Act of 2022, which was introduced today and, if passed in its current form, would authorize for appropriations of $535 million in annual funding to support sickle cell d

  • GlobeNewswire

    GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference

    Keynote by Admiral Rachel Levine, M.D., Assistant Secretary for Health, U.S. Department of Health and Human ServicesSOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 11th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Wednesday, September 14th. The virtual conference, which takes place during National Sickle Cell Awareness Mon

  • GlobeNewswire

    Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology

    Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address the full spectrum of critical needs in the underserved sickle cell community Transaction valued at $68.50 per Global Blood Therapeutics share in cash, for a total enterprise value of approximately $5.4 billion NEW YORK and SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pfize